Table 1.
Patient and treatment characteristics.
| Parameter | Results (%) |
|---|---|
|
Total number of patients Age at primary diagnosis in years, median (range) |
60 (1 0 0) 67.7 (33–83) |
|
Male gender, n (%) Median follow-up time in years (range) ECOG, median (range) |
45 (75.0) 2.2 (0.6–9.3) 1 (0–2) |
| Primary tumor histology and disease stage, n (%) | |
|
NSCLC Primary, non-metastatic NSCLC Adenocarcinoma Squamous-cell carcinoma Loco-regionally recurrent NSCLC Adenocarcinoma Squamous-cell carcinoma Large-cell carcinoma Oligometastatic disease NSCLC Colorectal adenocarcinoma Head-and-Neck cancer Melanoma Sarcoma Other1 Polymetastatic disease NSCLC |
27 (45.0) 12 (20.0) 5 (8.3) 7 (11.7) 15 (25.0) 10 (16.7) 4 (6.7) 1 (1.7) 30 (50.0) 10 (17.5) 4 (6.7) 4 (6.7) 3 (5.0) 3 (5.0) 6 (10) 3 (5.0) 3 (5.0) |
|
COPD Gold 1 Gold 2 Gold 3 Gold 4 |
21 (35.0) 3 (5.0) 8 (13.3) 7 (11.7) 3 (5.0) |
|
OMD status (all patients) De-novo Repeat Induced |
30 (50.0) 8 (13.3) 13 (21.7) 9 (15.0) |
|
Alive at time of analysis, n (%) Radiotherapy of primary tumor, n (%) Radiotherapy of pulmonary metastasis, n (%) Prior treatment Surgery Radiotherapy Type-I re-irradiation Chemotherapy Immunotherapy Targeted therapy Cardiotoxic systemic therapy* Systemic therapy < 6 months before index radiotherapy |
21 (35.0) 27 (45.0) 33 (55.0) 47 (78.3) 29 (48.3) 22 (36.7) 13 (21.7) 25 (41.7) 14 (23.3) 5 (8.3) 17 (28.3) 19 (31.7) |
|
Cardiovascular comorbidities at baseline, n (%) Coronary artery disease Ischemic heart disease Prior myocardial infarction Non-coronary atherosclerosisNon-ischemic heart disease (congestive heart failure)Peripheral Arterial Disease (PAD)2 Pulmonary hypertension Valvulopathy Prior stroke / TIA Atrial fibrillation Other arrhythmias3 Hypertension Dyslipidemia Diabetes mellitus Smoking history |
44 (73.3) 13 (21.7) 1 (1.7) 3 (5.0) 10 (16.7) 8 (13.3) 11 (18.3) 1 (1.7) 9 (15.0) 4 (6.7) 9 (15.0) 10 (16.7) 30 (50.0) 11 (18.3) 10 (16.7) 48 (80.0) |
|
Treatment volume characteristics Longest tumor diameter in cm, (range) <3 cm 3–7 cm >7 cm PTV location Overlap with PBT Overlap with trachea Overlap with heart Overlap with esophagus Overlap with Aorta Overlap with pulmonary artery PTV to heart distance in cm, median (range) Distance < 1 cm, n (%) |
16 (26.7) 40 (66.7) 4 (6.7) 60 (100.0) 14 (23.3) 15 (25.0) 11 (18.3) 16 (26.7) 44 (73.3) 1.2 (0–6.3) 24 (40.0) |
|
Treatment characteristics Single dose in Gy, median (range) Number of fractions, median (range) Total dose in Gray, median (range) EQD2_10 dose in Gray, median (range) Prescription Isodose, mode (%, range) V100% of PTV in %, median (range) D0.1 cc of PTV in EQD2_10 in Gy, median (range) GTV size in cm3, median (range) PTV size in cm3, median (range) Most frequent fractionation schemesEight fractions (8fx) 8 × 6 Gy@65% 8 × 5 Gy@65% Ten fractions (10fx) 10 × 5 Gy@80% 10 × 4.5 Gy@80% |
5 (3–7.5) 8 (5–12) 45 (30–60) 55.2 (33.0 – 88.0) 65 (65–80) 96.0 (9.5–99.4) 86.5 (43.1–120.6) 12.5 (0.6–114.9) 30.0 (6.0–199.0) 30 (50.0) 13 (21.7) 13 (21.7) 25 (41.7) 9 (15.0) 7 (11.7) |
1
Includes small-cell lung cancer (SCLC), prostate cancer, mesothelioma, pancreatic cancer and urothelial cancer.
2
Includes ectasia and aneurysm.
3
Includes AV-block, left/right bundle branch block and bifascicular block. *Cardiotoxic agents included: Taxanes (Docetaxel, Paclitaxel), Antimetoblites (5-Fluoruracil), MEK inhibitors (Dabrafenib), Anthracyclines (Epirubicin), EGFR-TKI (Osimertinib) and other TKIs (Pralsetinib, Dabrafenib, Crizotinib).